TABLE 1.
Trial | Study design | Recruitment period | Median follow-up (month) | Interventions | Sample size |
---|---|---|---|---|---|
COU-AA-301 | Phase 3, multicenter, double-blind, RCT | May 2008 to Jul 2009 | 20.2 | Abiraterone + prednisone vs. placebo + prednisone | 797 vs. 398 |
Sun et al. (2016) | Phase 3, multicenter, double-blind, RCT | Aug 2012 to Nov 2013 | 12.9 | Abiraterone + prednisone vs. placebo + prednisone | 143 vs. 71 |
AFFIRM | Phase 3, multicenter, double-blind, RCT | Sep 2009 to Nov 2010 | 14.4 | Enzalutamide vs. placebo | 800 vs. 399 |
TROPIC | Phase 3, multicenter, open-label, RCT | Jan 2007 to Oct 2008 | 12.8 | Cabazitaxel + prednisone vs. mitoxantrone + prednisone | 378 vs. 377 |
ALSYMPCA | Phase 3, multicenter, open-label, RCT | Jun 2008 to Feb 2011 | NA | Radium-223 vs. placebo | 325 a vs. 174 a |
Abbreviations: RCT, randomized controlled trial; NA, not available.
Data of patients with previous docetaxel use.